Taysha Gene Therapies (TSHA) Set to Announce Quarterly Earnings on Monday

Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) will announce its quarterly earnings results before the market opens on Monday, May 16th. Analysts expect the company to announce earnings of ($1.03) per share for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) last released its quarterly earnings results on Thursday, March 31st. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.21) by ($0.11). On average, analysts expect Taysha Gene Therapies to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

TSHA opened at $3.19 on Thursday. The firm has a market cap of $129.11 million, a P/E ratio of -0.69 and a beta of 2.23. Taysha Gene Therapies has a 12 month low of $3.16 and a 12 month high of $26.99. The company has a current ratio of 3.08, a quick ratio of 3.08 and a debt-to-equity ratio of 0.39. The stock has a 50-day moving average of $5.44 and a 200 day moving average of $9.12.

Several research analysts recently commented on TSHA shares. Robert W. Baird started coverage on Taysha Gene Therapies in a research report on Wednesday, March 9th. They issued an “outperform” rating and a $26.00 price target for the company. Needham & Company LLC dropped their target price on Taysha Gene Therapies from $47.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, April 1st. Sumitomo Mitsui Financial Group started coverage on Taysha Gene Therapies in a research report on Friday, February 18th. They set an “outperform” rating and a $25.00 target price for the company. Zacks Investment Research lowered Taysha Gene Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 6th. Finally, Wells Fargo & Company started coverage on Taysha Gene Therapies in a research report on Tuesday, March 1st. They set an “overweight” rating and a $25.00 target price for the company. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.14.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its stake in Taysha Gene Therapies by 75.1% in the second quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $32,000 after buying an additional 657 shares in the last quarter. Swiss National Bank raised its stake in Taysha Gene Therapies by 9.3% in the first quarter. Swiss National Bank now owns 41,000 shares of the company’s stock worth $267,000 after buying an additional 3,500 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Taysha Gene Therapies by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 162,560 shares of the company’s stock worth $1,894,000 after buying an additional 4,153 shares in the last quarter. Citigroup Inc. raised its stake in Taysha Gene Therapies by 219.4% in the fourth quarter. Citigroup Inc. now owns 10,607 shares of the company’s stock worth $124,000 after buying an additional 7,286 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in Taysha Gene Therapies by 126.5% in the fourth quarter. Legal & General Group Plc now owns 16,100 shares of the company’s stock worth $187,000 after buying an additional 8,993 shares in the last quarter. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Taysha Gene Therapies Company Profile (Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

See Also